ISSN: 1040-8428
Journal Home
Journal Guideline
Critical Reviews in Oncology/Hematology Q1 Unclaimed
Critical Reviews in Oncology/Hematology is a journal indexed in SJR in Hematology and Oncology with an H index of 144. It has an SJR impact factor of 1,572 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,572.
Critical Reviews in Oncology/Hematology focuses its scope in these topics and keywords: cancer, treatment, relapsed, review, systematic, radiotherapy, role, immunity, il, hematopoietic, ...
Type: Journal
Type of Copyright:
Languages: English
Open Access Policy: Open Choice
Type of publications:
Publication frecuency: -
- €
Inmediate OANPD
Embargoed OA0 €
Non OAMetrics
1,572
SJR Impact factor144
H Index181
Total Docs (Last Year)656
Total Docs (3 years)17156
Total Refs3733
Total Cites (3 years)644
Citable Docs (3 years)5.58
Cites/Doc (2 years)94.78
Ref/DocOther journals with similar parameters
Journal of Hematology and Oncology Q1
Blood Q1
Blood Cancer Journal Q1
The Lancet Haematology Q1
Leukemia Q1
Compare this journals
Aims and Scope
Best articles by citations
Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma
View moreThe role of adjuvant chemotherapy in the treatment of adult soft tissue sarcomas
View moreThe cellular biology of B-cell chronic lymphocytic leukemia
View morePhosphofructokinase: A mediator of glycolytic flux in cancer progression
View moreAutologous spheroid culture: a screening tool for human brain tumour invasion
View moreRules allowing the reimbursement of cares of elderly cancer patients in France
View moreThe role of cytokines in the normal and neoplastic pituitary
View moreChanges in apoptosis during the development of colorectal cancer: a systematic review of the literature
View moreCytoskeletal and adhesion protein changes during neoplastic progression of human prostate epithelial cells
View moreContribution of three-dimensional culture to cancer research
View moreProstate cancer incidence and mortality trends among elderly and adult Europeans
View moreThe treatment of undifferentiated neuroendocrine tumors
View moreBenign breast disease and cancer risk
View moreImportant issues in planning and conducting multi-centre randomised trials in cancer and publishing their results
View morePrescribers' attitudes toward elderly breast cancer patients. Discrimination or empathy?
View moreIncidence of cancer after immunosuppressive treatment for heart transplantation
View moreManagement of bone metastases in cancer: A review
View moreClinical benefits of stabilisation with second line chemotherapy in patients with metastatic colorectal cancer
View moreTiming of breast cancer surgery in relation to the menstrual cycle: an update of developments
View moreThe role of systemic chemotherapy in the treatment of brain metastases from small-cell lung cancer
View moreDirect intratumoral chemotherapy
View moreTreatment of patients with high-grade non-Hodgkin's lymphoma aged over 70 years with an all-oral regimen combining idarubicin, etoposide and alkylators
View moreEconomic evaluations of systemic adjuvant breast cancer treatments: methodological issues and a critical review
View moreMicroinvasive squamous cell cervical carcinoma
View more
Comments